References
- Akdis CA, Bachert C, Cingi C, Dykewicz MS, Hellings PW, Naclerio RM, et al. Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2013;131(6):1479-90. https://doi.org/10.1016/j.jaci.2013.02.036 PMid:23587334
- Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449-56.e4. https://doi.org/10.1016/j.jaci.2015.12.1324 PMid:26949058
- Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl 29):1-464. https://doi.org/10.4193/rhin20.600 PMid:32077450
- Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard P, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 2001;107(1):73-80. https://doi.org/10.1067/mai.2001.111593 PMid:11149994
- Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, et al. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2019;7(2):589-96.e3. https://doi.org/10.1016/j.jaip.2018.08.021 PMid:30193936
- Promsopa C, Kansara S, Citardi MJ, Fakhri S, Porter P, Luong A. Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol. 2016;6(4):373-7. https://doi.org/10.1002/alr.21674 PMid:26678021
- Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016;4(4):565-72. https://doi.org/10.1016/j.jaip.2016.04.012 PMid:27393770
- Bachert C, Claeys SE, Tomassen P, van Zele T, Zhang N. Rhinosinusitis and asthma: A link for asthma severity. Curr Allergy Asthma Rep. 2010;10(3):194-201. https://doi.org/10.1007/s11882-010-0096-0 PMid:20424997
- Huang CC, Wang CH, Fu CH, Huang CC, Chang PH, Chen IW, et al. The link between chronic rhinosinusitis and asthma: A questionnaire-based study. Medicine (Baltimore). 2016;95(31):e4294. https://doi.org/10.1097/md.0000000000004294 PMid:27495032
- Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014;28(3):192-8. https://doi.org/10.2500/ajra.2014.28.4033 PMid:24980230
- Wenzel SE. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716-25. https://doi.org/10.1038/nm.2678 PMid:22561835
- Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global Strategy for Asthma Management and Prevention: GINA executive summary. Eur Respir J. 2008;31:143-78. https://doi.org/10.1183/09031936.00138707
- Koennecke M, Klimek L, Mullol J, Gevaert P, Wollenderg B. Subtyping of polyposis nasi: Phenotypes, endotypes and comorbidities. Allergo J Int. 2018;27(2):56-65. https://doi.org/10.1007/s40629-017-0048-5 PMid:29564208
- Corren J. New targeted therapies for uncontrolled asthma. J Allergy Clin Immunol Pract. 2019;7(5):1394-403. https://doi.org/10.1016/j.jaip.2019.03.022 PMid:31076057
- De Filippo M, Votto M, Licari A, Pagella F, Benazzo M, Ciprandi G, et al. Novel therapeutic approaches targeting endotypes of severe airway disease. Expert Rev Respir Med. 2021;15(10):1303-16. https://doi.org/10.1080/17476348.2021.1937132 PMid:34056983
- Wu D, Bleier BS, Li L, Zhan X, Zhang L, Wei Y, et al. Clinical phenotypes of nasal polyps and comorbid asthma based on cluster analysis of disease history. J Allergy Clin Immunol Pract. 2018;6(4):1297-305.e1 https://doi.org/10.1016/j.jaip.2017.09.020 PMid:29100865
- Fokkens WJ, Lund V, Bachert C, Mullol J, Bousquet J, Canonica GW, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312-9. https://doi.org/10.1111/all.13875 PMid:31090937
- Kariyawasam HH, James LK, Gane SB. Dupilumab: Clinical efficacy of blocking IL-4/IL-13 signalling in chronic rhinosinusitis with nasal polyps. Drug Des Devel Ther. 2020;14:1757-69. https://doi.org/10.2147/dddt.s243053 PMid:32440101
- Boiko NV, Lodochkina OE, Kit MM, Kuleshova VG, Nedashkovskaya NG. Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma. Vestn Otorinolaringol. 2021;86(2):43-8. https://doi.org/10.17116/otorino20218602143 PMid:33929151
- Koski RR, Hill L, Taavola K. Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps. J Pharm Technol. 2022;38(5):289-96. https://doi.org/10.1177/87551225221105749 PMid:36046351
- Legrand F, Klion AD. Biologic therapies targeting eosinophils: Current status and future prospects. J Allergy Clin Immunol Pract. 2015;3(2):167-74. https://doi.org/10.1016/j.jaip.2015.01.013 PMid:25754717
- Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: A fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046. https://doi.org/10.1183/13993003.01046-2019 PMid:31249014
- Gallo S, Russo F, Mozzanica F, Preti A, Bandi F, Costantino C, et al. Prognostic value of the Sinonasal Outcome Test 22 (SNOT-22) in chronic rhinosinusitis. Acta Otorhinolaryngol Ital. 2020;40(2):113-21. https://doi.org/10.14639/0392-100X-N0364 PMid:32469005
- Matsunaga NY, Ribeiro MA, Saad IA, Morcillo AM, Ribeiro JD, Toro AA. Evaluation of quality of life according to asthma control and asthma severity in children and adolescents. J Bras Pneumol. 2015;41(6):502-8. https://doi.org/10.1590/S1806-37562015000000186 PMid:26785958
- Máspero J. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: Clinical trial evidence and future prospects. Ther Adv Respir Dis. 2017;11(8):311-25. https://doi.org/10.1177/1753465817717134 PMid:28683596
- Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol. 2001;86(5):494-507; quiz 507-8. https://doi.org/10.1016/s1081-1206(10)62896-7 PMid:11379801
- Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133-41. https://doi.org/10.1016/j.jaci.2006.05.031 PMid:17088140
- Boiko NV, Kim AS, Stagnieva IV, Simbirtsev AS. Proinflammatory cytokine content in the saliva of children suffering from chronic tonsillitis. Vestn Otorinolaringol. 2019;84(3):26-31. https://doi.org/10.17116/otorino20198403126 PMid:31486423
- Wu Q, Zhang Y, Kong W, Wang X, Yuan L, Zheng R, et al. Which is the best biologic for nasal polyps: Dupilumab, omalizumab, or mepolizumab? A network meta-analysis. Int Arch Allergy Immunol. 2022;183(3):279-88. https://doi.org/10.1159/000519228 PMid:34607329